Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

THA clinicals

Executive Summary

FDA said in a March 24 Talk Paper that the agency "will do everything possible to encourage Dr. Summers not to abandon any of his current patients." FDA has been investigating the researcher's study of THA in 35 patients with Alzheimer's disease, published in the Nov. 13, 1986 issue of The New England Journal of Medicine. "If patients are denied treatment by Dr. Summers, FDA has arranged with Warner-Lambert to set up a special protocol to provide continued treatment," the Talk Paper states.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS013426

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel